• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

BenchSci Raises $63 Million to Expand AI-Powered Software Platform


Funding brings total investment to $123 million.

BenchSci (Toronto, Canada) a company devising machine learning applications for novel medicine development, has announced a $63 million Series C (US $50 Million) funding round led by Inovia Capital and TCV, with participation from existing investors. The funding allows BenchSci to expedite the expansion of its AI-powered software platform that accelerates research in 16 of the Top 20 pharma companies and over 4,500 research centers worldwide.

Liran Belenzon, CEO, BenchSci, commented: “We're using breakthrough machine learning technology to shape the future of how life science companies conduct research, from identifying targets, to planning experiments, to determining clinical trial risks. The confidence demonstrated by global pharmaceutical companies who are early adopters of our new solutions was enough to convince Inovia Capital to fund another round and prompt TCV to back our meteoric hypergrowth. ”

Related Videos
Related Content